Learning from BISCAY: The future of biomarker-based trial design in bladder cancer
- PMID: 34256907
- DOI: 10.1016/j.ccell.2021.06.011
Learning from BISCAY: The future of biomarker-based trial design in bladder cancer
Abstract
A recent article in Nature Medicine explored the combination of immunotherapy with multiple distinct targeted therapies in patients with metastatic urothelial cancer, employing a biomarker-driven approach. Herein, we discuss the merits of this ambitious study and highlight the need for larger biomarker-based randomized trials to arrive at definitive clinical conclusions.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests S.K.P. declares the following: honoraria—Novartis, Medivation, and Astellas Pharma; consulting or advisory role—Pfizer, Novartis, Aveo, and Myriad; pharmaceuticals—Genentech, Exelixis, Bristol-Myers Squibb, and Astellas Pharma; and research funding—Medivation.
Comment on
-
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.Nat Med. 2021 May;27(5):793-801. doi: 10.1038/s41591-021-01317-6. Epub 2021 May 3. Nat Med. 2021. PMID: 33941921 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
